Conversion from Cyclosporine A to Once-Daily Tacrolimus in Stable Kidney Transplant Recipients: a Multicenter Prosepctive Study
石炳毅,韩文科,张小东,季曙明,马潞林,刘航,徐达,孙煦勇,林涛
DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2014.02.004
2014-01-01
Abstract:Objective To evaluate the safety and efficacy of switch from cyclosporine A (CsA) to prolonged-release tacrolimus in adult stable kidney transplant recipients.Method This multicenter,open-lable,single arm,and uncontroled study in stable adult kidney transplant recipients who had been immunosuppresively treated with CsA and met the inclusion/exclusion creteria were eligible for enrollment.CsA was switched to prolonged-release (once daily) tacrolimus at the initial dose of 0.05 ～0.1 mg· kg-1 · d-1.Change of serum creatinine level (primary endpoint),as well as serume creatinine,acute rejection,tacrolimus trough concentration,blood pressure,blood lipid,ALT,AST,HDL,TC,TG,LDL,TBIL,fasting blood glucose,gingival hyperplasia and hypertrichosis (second endpoint) during the 24-week of study time were assessed.Result From November 2010 to November 2012,there were 105 patients enrolled with similar baseline characteristics.There was no death and acute rejection during the 24-week follow-up.Serum creatinine remained stable after conversion to tacrolimus QD from CsA.TC,TG and LDL after conversion were significantly reduced.HDL,ALT and AST showed no significant change,and TBIL levels were lower at 1st,2nd,4th,8th,and 12th week after conversion than those at the baseline.Hypertrichosis and gingival hyperplasia in more than 90％ of recipients were alleviated at week 24 after conversion.Conclusion The conversion from CsA to Tacrolimus QD was safe and effective in stable kidney transplant recipients.Compared with the baseline,renal function was improved significantly (P＜0.01) at week 24 after conversion,gingival hyperplasia and hypertrichosis improved significantly (P＜0.01),and no acute rejection episodes occurred.